细胞治疗用培养基市场:各产品类型，各细胞治疗类型，各产业规模，各终端用户类型，各主要地区:到2035年前的产业趋势与全球预测

全球细胞治疗介质市场规模预计将从目前的 11 亿美元增长到 2035 年的 44 亿美元，到 2035 年的预测期间复合年增长率为 12%。

在 FDA 批准的细胞疗法在治疗肿瘤、罕见和慢性疾病方面取得的众多进步和已被证明的成功的推动下，这种疗法引起了医疗保健行业新兴参与者的极大关注。值得注意的是，自2019年以来，已有超过1,000项针对细胞疗法的临床试验启动。此外，超过 35 种细胞和基因疗法已在不同地区商业化。最近批准的细胞疗法的着名例子包括 Breyanzi(R)、Carvykti(TM) 和 Abecma(R)。

近年来，对细胞疗法生产的监管越来越严格。为了解决与製造细胞治疗耗材相关的监管课题，超过 90% 的细胞治疗开发商依赖拥有必要专业知识的供应商来提供高品质的原料、培养基、试剂盒，我们选择外包试剂和细胞外基质。目前，超过 80 家公司提供超过 450 种研究级和治疗级成分。此外，一些公司声称拥有 GMP 认证的设施，用于生产用于各种人类细胞（包括 T 细胞、干细胞、树突状细胞和 NK 细胞）的消耗品。

随着细胞治疗领域的不断发展，预计行业内的创新和合作将激增，从而为新的治疗方案铺平道路，这些方案有可能改变患者护理并扩大再生医学的视野。

本报告提供全球细胞治疗用培养基市场相关调查，提供市场概要，以及各产品类型，各细胞治疗类型，各产业规模，各终端用户类型，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 摘要整理

第3章 简介

第4章 市场形势

第5章 企业竞争力分析

第6章 主要产业品牌定位

第7章 企业简介

• 章概要
• STEMCELL Technologies
• Miltenyi Biotec
• Thermo Fisher Scientific
• Bio-Techne
• Irvine Scientific
• Lonza
• Sartorius
• BD Biosciences
• Corning
• CellGenix

第8章 最近的趋势与措施

第9章 细胞治疗消耗品供应商的恰当的合作伙伴分析

第10章 始祖分析价格策略

第11章 需求分析

第12章 市场预测与机会分析

第13章 今后趋势与今后的成长机会

第14章 结论

第15章 采访记录

第16章 附录I:表格形式资料

第17章 附录II:企业及组织一览

CELL THERAPY MEDIA MARKET: OVERVIEW

As per Roots Analysis, the global cell therapy media market is estimated to grow from USD 1.1 billion in the current year to USD 4.4 billion by 2035, at a CAGR of ~12% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

• Culture Media, Kits
• Cell Culture Reagents
• Extracellular Matrices

Type of Cell Therapy

• T-Cell Therapy
• Stem Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy

Scale of Operation

• Clinical
• Commercial

Type of End User

• Industry
• Non-Industry

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

CELL THERAPY MEDIA MARKET: GROWTH AND TRENDS

Driven by numerous advancements and the proven success of FDA approved cell therapies for the treatment of oncological disorders, rare diseases, and chronic diseases, this therapeutic modality has garnered considerable attention of players engaged in the healthcare industry. It is worth highlighting that, since 2019, more than 1,000 clinical trials focused on cell therapies have been initiated. Additionally, over 35 cell and gene therapies have been commercialized, across various geographical locations. Notable examples of recently approved cell therapies include Breyanzi(R), Carvykti(TM) and Abecma(R).

In recent years, regulatory stringency has increased for the production of cell therapy. In order to address the regulatory challenges linked to the production of cell therapy consumables, over 90% of cell therapy developers choose to outsource culture media, kits, reagents and extracellular matrices to suppliers who possess the necessary expertise to deliver high-quality raw materials. At present, more than 80 players are offering more than 450 research and / or therapeutic grade raw materials. In addition, some companies claim to have GMP certified facilities for the production of consumables, which are intended to be used for a range of human cells, including T-cells, stem cells, dendritic cells and NK cells.

As the landscape of cell therapy continues to evolve, we anticipate a surge in innovation and collaboration within the industry, paving the way for new therapeutic options that could transform patient care and expand the horizons of regenerative medicine.

CELL THERAPY MEDIA MARKET: KEY INSIGHTS

The report delves into the current state of the cell therapy media market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Leveraging their expertise, over 450 types of kits, media, reagents and extracellular matrices have been manufactured by consumable providers for research and therapeutic purposes.

2. The market features the presence of over 80 firms across the globe; the majority of these stakeholders are emerging players based in North America.

3. A larger proportion of the kits available in the cell therapy domain comprises different types of reagents; of these, 60% are intended for use with stem cell therapies and nearly 80% are stored in refrigerated conditions.

4. Media developers are offering products for a broad range of cell therapies; nearly 90% of such players are providing media in the volume range of 100 to 500 ml.

5. Predominantly, the cell therapy reagents are intended to be used at the discovery scale of operation for a wide spectrum of functions, including cell expansion and proliferation.

6. The market landscape of matrices, which typically have a shelf life of 1 to 1.5 years, is well distributed in terms of type of ECM coating and type of formulation.

7. In pursuit of gaining a competitive edge, cell therapy consumable providers are upgrading their existing technologies and expanding their product portfolios.

8. Many companies have undertaken strategic initiatives, including partnerships, acquisitions and expansions, to augment their existing capabilities.

9. We expect industry stakeholders to continue to forge strategic alliances with niche / specialized players engaged in this domain to further augment their respective product offerings.

10. Over the years, stakeholders within this industry have established strong brand positions by undertaking a range of initiatives to further advance the development of raw materials for cell therapies.

11. Cost is a key determinant for the adoption of consumables in a cell therapy manufacturing process.

12. In 2035, the commercial scale of operation is likely to account for 75% of the total demand for cell therapy consumables; this is attributed to the expected surge in the anticipated approvals of multiple cell therapies.

13. A paradigm shift from animal-based to animal component free formulations, combined with stringent regulatory guidelines, is likely to drive the growth of the cell therapy consumables market at an annualized rate of 12%.

CELL THERAPY MEDIA MARKET: KEY SEGMENTS

Extracellular Matrices is the Fastest Growing Segment in the Cell Therapy Media Market

Based on the type of product, the market is segmented into culture media, kits, cell culture reagents and extracellular matrices. It is worth highlighting that majority of the current cell therapy media market is captured by culture media.

T-Cell Therapy is Likely to Dominate the Cell Therapy Media Market During the Forecast Period

Based on the type of cell therapy, the market is segmented into T-Cell therapy, stem cell therapy, dendritic cell therapy and NK cell therapy. It is worth highlighting that the cell therapy consumables market for NK cell therapies is likely to grow at a relatively higher CAGR, during the forecast period. This can be attributed to the fact that currently, more than 75 NK cell therapy focused clinical studies are being evaluated for a myriad of disease indications. In the coming years, this number is anticipated to increase further, and this is likely to boost the market opportunity for such therapies.

By Scale of Operation, Commercial Scale is Likely to Dominate the Cell Therapy Media Market During the Forecast Period

Based on the scale of operation, the market is segmented into clinical and commercial scales. It is worth highlighting that the commercial scale cell therapy media market is likely to drive the market in the near future.

Industry Players Segment Accounts for the Largest Share of the Cell Therapy Media Market

Based on the type of end user, the market is segmented into industry and non-industry. It is worth highlighting that the cell therapy media market for industry players is likely to drive the market in the near future. This can be attributed to the fact that the industry players contribute significantly to the overall commercial market as majority of the approved therapies have been developed by such players.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. It is worth highlighting that, over the years, the market in Latin America is expected to grow at a higher CAGR.

Example Players in the Cell Therapy Media Market

• BD Biosciences
• Bio-Techne
• CellGenix
• Corning
• Irvine Scientific (Acquired by FUJIFILM)
• Lonza
• Miltenyi Biotech
• Sartorius
• STEMCELL Technologies
• Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Vice President of Business Development - Cell Therapy, Akadeum Life Sciences
• Chief Operating Officer, Cellular Engineering Technologies
• Director R&D, Cell Culture and Immunology, HiMedia Laboratories
• Assistant R&D Manager, Animal Cell Culture, HiMedia Laboratories

CELL THERAPY MEDIA MARKET: RESEARCH COVERAGE

• The report features an in-depth analysis of the cell therapy media market, focusing on key market segments, including type of product, type of cell therapy, scale of operation, type of end user and key geographical regions.
• A comprehensive evaluation of companies offering cell culture consumables and cell culture media, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of product (kits, media, reagents and extracellular matrices), number and location of consumable facilities, accreditations received, type of end-user (industry and non-industry), cell culture media compatibility (serum free media, xeno free media and both), type of cell therapy (T-cell therapies, stem cell therapies, NK cell therapies, dendritic cell therapies and others), type of function (cell proliferation, cell expansion, cell differentiation, cell activation, cell isolation, cell attachment), kit components (supplements / reagents, growth / induction medium, expansion medium, differentiation medium and others), type of ECM coating (laminin, fibronectin, vitronectin, basement membrane extract and others), type of formulation (powder, liquid, pre-coated cultureware), shelf life (6-12 months, 13-18 months, 19-24 months and 25-36 months), scale of operation (discovery, preclinical, clinical and commercial), application area (research use and therapeutic use), storage temperature (refrigerated, frozen, ultra-low and room temperature), as well as volume of media, reagents and extracellular matrices.
• A comprehensive competitive analysis of companies operating in the cell culture consumable and cell culture media market, examining factors such as supplier strength, portfolio strength and number of products offered.
• A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
• In-depth profiles of key industry players in cell therapy consumables and cell culture media market, focusing on company overviews, product portfolio, consumable facilities, recent developments and an informed future outlook.
• An analysis of recent developments within the cell culture consumables and cell culture media market, since 2016, covering partnerships and collaborations, mergers and acquisitions, and expansion initiatives.
• A detailed evaluation of over 250 cell therapy developers that are most likely to collaborate with cell culture consumables and cell culture media providers. This analysis considers various relevant parameters, including developer strength (which takes into account a company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), and availability of other cell therapy capabilities.
• A proprietary Roots Analysis competitive pricing framework, which analyzes the competitive position of various companies engaged in cell culture consumables and cell culture media market, by taking into consideration the prices and features of their consumable offerings (such as media and extracellular matrices). In addition, it presents an equation devised to calculate the likely price of cell therapy consumables based upon their characteristics.
• Informed estimates of the annual demand for cell culture consumables and cell culture media (in terms of volume of media required for total number of cells), based on scale of operation and key geographical regions.
• A comprehensive analysis of emerging trends and future growth prospects in the cell culture consumables and media market. It includes details related to the significance of automation in cell therapy manufacturing processes and the benefits of single use technologies for the production of cell therapies.

KEY QUESTIONS ANSWERED IN THIS REPORT

• What are the factors driving the cell therapy consumables market?
• How many players are engaged in offering cell culture media for manufacturing cell therapies?
• How many players are engaged in offering kits for manufacturing cell therapies?
• How many media products are available in the market for culturing cell therapies?
• What are the partnership and collaboration trends observed in the cell therapy consumables domain?
• Which geographical segment captures the largest market share in the current cell therapy consumables market?
• Which type of product contributes to the largest share of the cell therapy consumables market?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Context and Background
• 3.2. Introduction to Cell Therapies
• 3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
• 3.4. Classification of Cell Therapy Products
• 3.5. Overview of Cell Therapy Development and Manufacturing
• 3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
• 3.7. Types of Cell Therapy Consumables
• 3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
• 3.9. Future Perspectives

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. List of Cell Therapy Kit Providers
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Location of Kit Manufacturing Facilities
  • 4.2.5. Analysis by Certifications / Accreditations Received
  • 4.2.6. Analysis by Type of End-User
  • 4.2.7. Analysis by Type of Cell Therapy
  • 4.2.8. Analysis by Type of Function
  • 4.2.9. Analysis by Kit Components
  • 4.2.10. Analysis by Storage Temperature
  • 4.2.11. Analysis by Scale of Operation
  • 4.2.12. Analysis by Application Area
  • 4.2.13. Analysis by Application Area and Geography
• 4.3. List of Cell Therapy Media Providers
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters
  • 4.3.4. Analysis by Location of Media Manufacturing Facilities
  • 4.3.5. Analysis by Certifications / Accreditations Received
  • 4.3.6. Analysis by Type of End-User
  • 4.3.7. Analysis by Type of Cell Therapy
  • 4.3.8. Analysis by Media Compatibility
  • 4.3.9. Analysis by Type of Function
  • 4.3.10. Analysis by Storage Temperature
  • 4.3.11. Analysis by Volume of Media
  • 4.3.12. Analysis by Scale of Operation
  • 4.3.13. Analysis by Application Area
  • 4.3.14. Analysis by Application Area and Geography
• 4.4. List of Cell Therapy Reagent Providers
  • 4.4.1. Analysis by Year of Establishment
  • 4.4.2. Analysis by Company Size
  • 4.4.3. Analysis by Location of Headquarters
  • 4.4.4. Analysis by Location of Reagent Manufacturing Facilities
  • 4.4.5. Analysis by Certifications / Accreditations Received
  • 4.4.6. Analysis by Type of End-User
  • 4.4.7. Analysis by Type of Cell Therapy
  • 4.4.8. Analysis by Type of Function
  • 4.4.9. Analysis by Storage Temperature
  • 4.4.10. Analysis by Volume of Reagent
  • 4.4.11. Analysis by Scale of Operation
  • 4.4.12. Analysis by Application Area
  • 4.4.13. Analysis by Application Area and Geography
• 4.5. List of Cell Therapy Extracellular Matrix Providers
  • 4.5.1. Analysis by Year of Establishment
  • 4.5.2. Analysis by Company Size
  • 4.5.3. Analysis by Location of Headquarters
  • 4.5.4. Analysis by Location of Extracellular Matrix Manufacturing Facilities
  • 4.5.5. Analysis by Certifications / Accreditations Received
  • 4.5.6. Analysis by Type of End-User
  • 4.5.7. Analysis by Type of Stem Cell Therapy
  • 4.5.8. Analysis by Type of Function
  • 4.5.9. Analysis by Type of ECM Coating
  • 4.5.10. Analysis by Type of Formulation
  • 4.5.11. Analysis by Shelf Life
  • 4.5.12. Analysis by Storage Temperature
  • 4.5.13. Analysis by Volume of Extracellular Matrix
  • 4.5.14. Analysis by Scale of Operation
  • 4.5.15. Analysis by Application Area
  • 4.5.16. Analysis by Application Area and Geography

5. COMPANY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Key Assumptions and Parameters
• 5.3. Methodology
• 5.4. Cell Therapy Consumable Providers: Company Competitiveness Analysis
• 5.5. Cell Therapy Kits Providers
• 5.6. Cell Therapy Media Providers
  • 5.6.1. Cell Therapy Media Providers based in North America
  • 5.6.2. Cell Therapy Media Providers based in Europe
  • 5.6.3. Cell Therapy Media Providers based in Asia-Pacific
• 5.7. Cell Therapy Reagent Providers
• 5.8. Cell Therapy Extracellular Matrix Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS

• 6.1. Chapter Overview
• 6.2. Scope and Methodology
• 6.3. Brand Positioning: STEMCELL Technologies
• 6.4. Brand Positioning: Miltenyi Biotec
• 6.5. Brand Positioning: Thermo Fisher Scientific
• 6.6. Brand Positioning: Takara Bio
• 6.7. Brand Positioning: GeminiBio

7. COMPANY PROFILES

• 7.1. Chapter Overview
• 7.2. STEMCELL Technologies
  • 7.2.1. Company Overview
  • 7.2.2. Product Portfolio
  • 7.2.3. Recent Developments and Future Outlook
• 7.3. Miltenyi Biotec
  • 7.3.1. Company Overview
  • 7.3.2. Product Portfolio
  • 7.3.3. Recent Developments and Future Outlook
• 7.4. Thermo Fisher Scientific
  • 7.4.1. Company Overview
  • 7.4.2. Product Portfolio
  • 7.4.3. Recent Developments and Future Outlook
• 7.5. Bio-Techne
  • 7.5.1. Company Overview
  • 7.5.2. Product Portfolio
  • 7.5.3. Recent Developments and Future Outlook
• 7.6. Irvine Scientific
  • 7.6.1. Company Overview
  • 7.6.2. Product Portfolio
  • 7.6.3. Recent Developments and Future Outlook
• 7.7. Lonza
  • 7.7.1. Company Overview
  • 7.7.2. Product Portfolio
  • 7.7.3. Recent Developments and Future Outlook
• 7.8. Sartorius
  • 7.8.1. Company Overview
  • 7.8.2. Product Portfolio
  • 7.8.3. Recent Developments and Future Outlook
• 7.9. BD Biosciences
  • 7.9.1. Company Overview
  • 7.9.2. Product Portfolio
  • 7.9.3. Recent Developments and Future Outlook
• 7.10. Corning
  • 7.10.1. Company Overview
  • 7.10.2. Product Portfolio
  • 7.10.3. Recent Developments and Future Outlook
• 7.11. CellGenix
  • 7.11.1. Company Overview
  • 7.11.2. Product Portfolio
  • 7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES

• 8.1. Chapter Overview
• 8.2. Partnership Models
• 8.3. Cell Therapy Consumables: Partnerships and Collaborations
  • 8.3.1. Analysis by Year of Partnership
  • 8.3.2. Analysis by Type of Partnership
  • 8.3.3. Analysis by Year and Type of Partnership
  • 8.3.4. Analysis by Type of Product
  • 8.3.5. Analysis by Type of Partnership and Type of Product
  • 8.3.6. Analysis by Type of Cell Therapy
  • 8.3.7. Analysis by Type of Product and Type of Cell Therapy
  • 8.3.8. Most Active Players: Analysis by Number of Partnerships
  • 8.3.9. Analysis by Region
    • 8.3.9.1. Intercontinental and Intracontinental Agreements
    • 8.3.9.2. Local and International Agreements
• 8.4. Cell Therapy Consumables: Mergers and Acquisitions
  • 8.4.1. Cumulative Year-wise Trend of Mergers and Acquisitions
  • 8.4.2. Analysis by Type of Agreement
  • 8.4.3. Analysis by Key Value Drivers
  • 8.4.4. Analysis by Year of Acquisition and Key Value Drivers
• 8.5. Cell Therapy Consumables: Recent Expansions
  • 8.5.1. Analysis by Year of Expansion
  • 8.5.2. Analysis by Type of Expansion
  • 8.5.3. Analysis by Year and Type of Expansion
  • 8.5.4. Analysis by Type of Product
  • 8.5.5. Analysis by Type of Expansion and Type of Product
  • 8.5.6. Analysis by Area of Expansion
  • 8.5.7. Most Active Players: Analysis by Number of Expansions
  • 8.5.8. Analysis by Region
    • 8.5.8.1. Analysis by Location of Facility (Continent-wise)
    • 8.5.8.2. Analysis by Location of Facility (Country-wise)
  • 8.5.9. Analysis by Type of Expansion and Location of Facility

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS

• 9.1. Chapter Overview
• 9.2. Scoring Criteria and Key Assumptions
• 9.3. Scope and Methodology
• 9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
  • 9.4.1. Likely Partners for Dendritic Cell Therapy Consumable Providers
  • 9.4.2. Likely Partners for NK Cell Therapy Consumable Providers
  • 9.4.3. Likely Partners for Stem Cell Therapy Consumable Providers
  • 9.4.4. Likely Partners for T-Cell Therapy Consumable Providers

10. ROOTS ANALYSIS PRICING STRATEGY

• 10.1. Chapter Overview
• 10.2. Roots Analysis Framework
  • 10.2.1. Theoretical Framework and Price Evaluation Hypothesis for Cell Therapy Media
    • 10.2.1.1. Methodology
    • 10.2.1.2. Results and Interpretation
      • 10.2.1.2.1. Cell Therapy Media Price Evaluation Matrix: Information on Volume of Media
      • 10.2.1.2.2. Cell Therapy Media Price Evaluation Matrix: Information on Media Compatibility
      • 10.2.1.2.3. Cell Therapy Media Price Evaluation Matrix: Information on Type of Product Manufacturing Practices
      • 10.2.1.2.4. Cell Therapy Media Price Evaluation Matrix: Information on Application Area
      • 10.2.1.2.5. Cell Therapy Media Price Evaluation Matrix: Information on Storage Temperature
      • 10.2.1.2.6. Cell Therapy Media Price Evaluation Matrix: Information on Type of Cell Therapy
      • 10.2.1.2.7. Cell Therapy Media Price Evaluation Matrix: Information on Type of Function
  • 10.2.2. Theoretical Framework and Price Evaluation Hypothesis of Cell Therapy Extracellular Matrices
    • 10.2.2.1. Methodology
    • 10.2.2.2. Results and Interpretation
      • 10.2.2.2.1. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of ECM Coating
      • 10.2.2.2.2. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Formulation
      • 10.2.2.2.3. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Volume of Extracellular Matrices
      • 10.2.2.2.4. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Storage Temperature
      • 10.2.2.2.5. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Shelf Life
      • 10.2.2.2.6. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Stem Cell Therapy
      • 10.2.2.2.7. Cell Therapy Extracellular Matrices Price Evaluation Matrix: Information on Type of Function

11. DEMAND ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Global Demand for Cell Therapy Consumables
  • 11.3.1. Global Demand for Cell Therapy Consumables for Planar Processes
  • 11.3.2. Global Demand for Cell Therapy Consumables for Suspension Processes
• 11.4. Analysis by Scale of Operation
• 11.5. Analysis by Geography

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 12.1. Chapter Overview
• 12.2. Key Assumptions and Methodology
• 12.3. Global Cell Therapy Consumables Market, till 2035
• 12.4. Cell Therapy Consumables Market: Analysis by Type of Product
  • 12.4.1. Cell Therapy Consumables Market for Extracellular Matrices, till 2035
  • 12.4.2. Cell Therapy Consumables Market for Kits, till 2035
  • 12.4.3. Cell Therapy Consumables Market for Media, till 2035
  • 12.4.4. Cell Therapy Consumables Market for Reagents, till 2035
• 12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
  • 12.5.1. Cell Therapy Consumables Market for Dendritic Cell Therapies, till 2035
  • 12.5.2. Cell Therapy Consumables Market for NK Cell Therapies, till 2035
  • 12.5.3. Cell Therapy Consumables Market for Stem Cell Therapies, till 2035
  • 12.5.4. Cell Therapy Consumables Market for T-Cell Therapies, till 2035
• 12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
  • 12.6.1. Cell Therapy Consumables Market for Clinical Operations, till 2035
  • 12.6.2. Cell Therapy Consumables Market for Commercial Operations, till 2035
• 12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
  • 12.7.1. Cell Therapy Consumables Market for Industry Players, till 2035
  • 12.7.2. Cell Therapy Consumables Market for Non-Industry Players, till 2035
• 12.8. Cell Therapy Consumables Market: Analysis by Geography
  • 12.8.1. Cell Therapy Consumables Market in North America, till 2035
    • 12.8.1.1. Cell Therapy Consumables Market in the US, till 2035
    • 12.8.1.2. Cell Therapy Consumables Market in Canada, till 2035
    • 12.8.1.3. Cell Therapy Consumables Market in Rest of North America, till 2035
  • 12.8.2. Cell Therapy Consumables Market in Europe, till 2035
    • 12.8.2.1. Cell Therapy Consumables Market in Spain, till 2035
    • 12.8.2.2. Cell Therapy Consumables Market in France, till 2035
    • 12.8.2.3. Cell Therapy Consumables Market in Germany, till 2035
    • 12.8.2.4. Cell Therapy Consumables Market in Italy, till 2035
    • 12.8.2.5. Cell Therapy Consumables Market in the Netherlands, till 2035
    • 12.8.2.6. Cell Therapy Consumables Market in the UK, till 2035
    • 12.8.2.7. Cell Therapy Consumables Market in Rest of Europe, till 2035
  • 12.8.3. Cell Therapy Consumables Market in Asia-Pacific, till 2035
    • 12.8.3.1. Cell Therapy Consumables Market in China, till 2035
    • 12.8.3.2. Cell Therapy Consumables Market in Korea, till 2035
    • 12.8.3.3. Cell Therapy Consumables Market in Rest of Asia-Pacific, till 2035
  • 12.8.4. Cell Therapy Consumables Market in Middle East and North Africa, till 2035
  • 12.8.5. Cell Therapy Consumables Market in Latin America, till 2035

13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES

• 13.1. Chapter Overview
• 13.2. Emerging Trends Related to Cell Culture Media
• 13.3. Automation of Cell Therapy Manufacturing Processes
• 13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

14. CONCLUDING REMARKS

15. INTERVIEW TRANSCRIPTS

• 15.1. Chapter Overview
• 15.2. Akadeum Life Sciences
  • 15.2.1. Interview Transcript: Michael Maloney, Vice President of Business Development - Cell Therapy
• 15.3. Cellular Engineering Technologies
  • 15.3.1. Interview Transcript: Anant Kamath, Chief Operating Officer
• 15.4. HiMedia Laboratories
  • 15.4.1. Interview Transcript: Vishal G. Warke, Director R&D, Cell Culture and Immunology and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

• Table 3.1 Cell Therapies: Applications
• Table 3.2 Differences between Cell Therapies and Other Biopharmaceuticals
• Table 3.3 Key Cell Therapy Manufacturing Steps
• Table 3.4 Types of Media Used in Cell Therapy Manufacturing
• Table 4.1 List of Cell Therapy Kit Providers
• Table 4.2 Cell Therapy Kits: Information on Type of Cell Therapy and Type of Function
• Table 4.3 Cell Therapy Kits: Information on Kit Components and Storage Temperature
• Table 4.4 Cell Therapy Kits: Information on Scale of Operation and Application Area
• Table 4.5 List of Cell Therapy Media Providers
• Table 4.6 Cell Therapy Media: Information on Type of Cell Therapy, Media Compatibility and Type of Function
• Table 4.7 Cell Therapy Media: Information on Storage Temperature and Volume of Media
• Table 4.8 Cell Therapy Media: Information on Scale of Operation and Application Area
• Table 4.9 List of Cell Therapy Reagent Providers
• Table 4.10 Cell Therapy Reagents: Information on Type of Cell Therapy and Type of Function
• Table 4.11 Cell Therapy Reagents: Information on Storage Temperature and Volume of Reagent
• Table 4.12 Cell Therapy Reagents: Information on Scale of Operation and Application Area
• Table 4.13 List of Cell Therapy Extracellular Matrix Providers
• Table 4.14 Cell Therapy Extracellular Matrices: Information on Type of Stem Cell Therapy and Type of Function
• Table 4.15 Cell Therapy Extracellular Matrices: Information on Type of ECM Coating and Type of Formulation
• Table 4.16 Cell Therapy Extracellular Matrices: Information on Shelf Life, Storage Temperature and Volume of Extracellular Matrix
• Table 4.17 Cell Therapy Extracellular Matrices: Information on Scale of Operation and Application Area
• Table 5.1 Company Competitiveness Analysis: Information on Peer Groups
• Table 7.1 List of Leading Cell Therapy Consumable Providers
• Table 7.2 STEMCELL Technologies: Company Overview
• Table 7.3 STEMCELL Technologies: Recent Developments and Future Outlook
• Table 7.4 Miltenyi Biotec: Company Overview
• Table 7.5 Miltenyi Biotec: Recent Developments and Future Outlook
• Table 7.6 Thermo Fisher Scientific: Company Overview
• Table 7.7 Thermo Fisher Scientific: Recent Developments and Future Outlook
• Table 7.8 Bio-Techne: Company Overview
• Table 7.9 Bio-Techne: Recent Developments and Future Outlook
• Table 7.10 Irvine Scientific: Company Overview
• Table 7.11 Irvine Scientific: Recent Developments and Future Outlook
• Table 7.12 Lonza: Company Overview
• Table 7.13 Sartorius: Company Overview
• Table 7.14 Sartorius: Recent Developments and Future Outlook
• Table 7.15 BD Biosciences: Company Overview
• Table 7.16 BD Biosciences: Recent Developments and Future Outlook
• Table 7.17 Corning: Company Overview
• Table 7.18 CellGenix: Company Overview
• Table 7.19 CellGenix: Recent Developments and Future Outlook
• Table 8.1 Cell Therapy Consumables: List of Partnerships and Collaborations, since 2015
• Table 8.2 Cell Therapy Consumables: Information on Location of Headquarters, since 2015
• Table 8.3 Mergers and Acquisitions: List of Mergers and Acquisitions, since 2016
• Table 8.4 Mergers and Acquisitions: Information on Key Value Drivers, since 2016
• Table 8.5 Cell Therapy Consumables: List of Recent Expansions, since 2017
• Table 9.1 Likely Partners for Dendritic Cell Therapy Consumable Providers
• Table 9.2 Likely Partners for NK Cell Therapy Consumable Providers
• Table 9.3 Likely Partners for Stem Cell Therapy Consumable Providers
• Table 9.4 Likely Partners for T-Cell Therapy Consumable Providers
• Table 10.1 Cell Therapy Media Price Evaluation Matrix: Based on Volume of Media (USD)
• Table 10.2 Cell Therapy Media Price Evaluation Matrix: Based on Media Compatibility (USD)
• Table 10.3 Cell Therapy Media Price Evaluation Matrix: Based on Type of Product Manufacturing Practices (USD)
• Table 10.4 Cell Therapy Media Price Evaluation Matrix: Based on Application Area (USD)
• Table 10.5 Cell Therapy Media Price Evaluation Matrix: Based on Storage Temperature (USD)
• Table 10.6 Cell Therapy Media Price Evaluation Matrix: Based on Type of Cell Therapy (USD)
• Table 10.7 Cell Therapy Media Price Evaluation Matrix: Based on Type of Function (USD)
• Table 10.8 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Type of ECM Coating (USD)
• Table 10.9 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Type of Formulation (USD)
• Table 10.10 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Volume of Extracellular Matrix (USD)
• Table 10.11 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Storage Temperature (USD)
• Table 10.12 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Shelf Life (USD)
• Table 10.13 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Type of Stem Cell Therapy (USD)
• Table 10.14 Cell Therapy Extracellular Matrices Price Evaluation Matrix: Based on Type of Function (USD)
• Table 15.1 Akadeum Life Sciences: Key Highlights
• Table 15.2 Cellular Engineering Technologies: Key Highlights
• Table 15.3 HiMedia Laboratories: Key Highlights
• Table 16.1 Cell Therapy Consumables: Distribution by Type of Product
• Table 16.2 Cell Therapy Consumable Providers: Distribution by Company Size and Location of Headquarters
• Table 16.3 Cell Therapy Kit Providers: Distribution by Year of Establishment
• Table 16.4 Cell Therapy Kit Providers: Distribution by Company Size
• Table 16.5 Cell Therapy Kit Providers: Distribution by Location of Headquarters
• Table 16.6 Cell Therapy Kit Providers: Distribution by Location of Kit Manufacturing Facilities
• Table 16.7 Cell Therapy Kit Providers: Distribution by Certifications / Accreditations Received
• Table 16.8 Cell Therapy Kit Providers: Distribution by Type of End-User
• Table 16.9 Cell Therapy Kits: Distribution by Type of Cell Therapy
• Table 16.10 Cell Therapy Kits: Distribution by Type of Function
• Table 16.11 Cell Therapy Kits: Distribution by Kit Components
• Table 16.12 Cell Therapy Kits: Distribution by Storage Temperature
• Table 16.13 Cell Therapy Kits: Distribution by Scale of Operation
• Table 16.14 Cell Therapy Kits: Distribution by Application Area
• Table 16.15 Cell Therapy Media Providers: Distribution by Year of Establishment
• Table 16.16 Cell Therapy Media Providers: Distribution by Company Size
• Table 16.17 Cell Therapy Media Providers: Distribution by Location of Headquarters
• Table 16.18 Cell Therapy Media Providers: Distribution by Location of Media Manufacturing Facilities
• Table 16.19 Cell Therapy Media Providers: Distribution by Certifications / Accreditations Received
• Table 16.20 Cell Therapy Media Providers: Distribution by Type of End-User
• Table 16.21 Cell Therapy Media: Distribution by Type of Cell Therapy
• Table 16.22 Cell Therapy Media: Distribution by Media Compatibility
• Table 16.23 Cell Therapy Media: Distribution by Type of Function
• Table 16.24 Cell Therapy Media: Distribution by Storage Temperature
• Table 16.25 Cell Therapy Media: Distribution by Volume of Media
• Table 16.26 Cell Therapy Media: Distribution by Scale of Operation
• Table 16.27 Cell Therapy Media: Distribution by Application Area
• Table 16.28 Cell Therapy Reagent Providers: Distribution by Year of Establishment
• Table 16.29 Cell Therapy Reagent Providers: Distribution by Company Size
• Table 16.30 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
• Table 16.31 Cell Therapy Reagent Providers: Distribution by Location of Reagent Manufacturing Facilities
• Table 16.32 Cell Therapy Reagent Providers: Distribution by Certifications / Accreditations Received
• Table 16.33 Cell Therapy Reagent Providers: Distribution by Type of End-User
• Table 16.34 Cell Therapy Reagents: Distribution by Type of Cell Therapy
• Table 16.35 Cell Therapy Reagents: Distribution by Type of Function
• Table 16.36 Cell Therapy Reagents: Distribution by Storage Temperature
• Table 16.37 Cell Therapy Reagents: Distribution by Volume of Reagent
• Table 16.38 Cell Therapy Reagents: Distribution by Scale of Operation
• Table 16.39 Cell Therapy Reagents: Distribution by Application Area
• Table 16.40 Cell Therapy Extracellular Matrix Providers: Distribution by Year of Establishment
• Table 16.41 Cell Therapy Extracellular Matrix Providers: Distribution by Company Size
• Table 16.42 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Headquarters
• Table 16.43 Cell Therapy Extracellular Matrix Providers: Distribution by Location of Extracellular Matrix Manufacturing Facilities
• Table 16.44 Cell Therapy Extracellular Matrix Providers: Distribution by Certifications / Accreditations Received
• Table 16.45 Cell Therapy Extracellular Matrix Providers: Distribution by Type of End-User
• Table 16.46 Cell Therapy Extracellular Matrices: Distribution by Type of Stem Cell Therapy
• Table 16.47 Cell Therapy Extracellular Matrices: Distribution by Type of Function
• Table 16.48 Cell Therapy Extracellular Matrices: Distribution by Type of ECM Coating
• Table 16.49 Cell Therapy Extracellular Matrices: Distribution by Type of Formulation
• Table 16.50 Cell Therapy Extracellular Matrices: Distribution by Shelf Life
• Table 16.51 Cell Therapy Extracellular Matrices: Distribution by Storage Temperature
• Table 16.52 Cell Therapy Extracellular Matrices: Distribution by Volume of Extracellular Matrix
• Table 16.53 Cell Therapy Extracellular Matrices: Distribution by Scale of Operation
• Table 16.54 Cell Therapy Extracellular Matrices: Distribution by Application Area
• Table 16.55 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2015
• Table 16.56 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 16.57 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, since 2015
• Table 16.58 Partnerships and Collaborations: Distribution by Type of Product
• Table 16.59 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
• Table 16.60 Partnerships and Collaborations: Distribution by Type of Cell Therapy
• Table 16.61 Partnerships and Collaborations: Distribution by Type of Product and Type of Cell Therapy
• Table 16.62 Most Active Players: Distribution by Number of Partnerships
• Table 16.63 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
• Table 16.64 Partnerships and Collaborations: Local and International Agreements
• Table 16.65 Mergers and Acquisitions: Cumulative Year-wise Trend, since 2016
• Table 16.66 Mergers and Acquisitions: Distribution by Type of Agreement
• Table 16.67 Mergers and Acquisitions: Distribution by Key Value Drivers
• Table 16.68 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers, since 2016
• Table 16.69 Recent Expansions: Cumulative Year-wise Trend, since 2017
• Table 16.70 Recent Expansions: Distribution by Type of Expansion
• Table 16.71 Recent Expansions: Distribution by Year and Type of Expansion, since 2017
• Table 16.72 Recent Expansions: Distribution by Type of Product
• Table 16.73 Recent Expansions: Distribution by Type of Expansion and Type of Product
• Table 16.74 Recent Expansions: Distribution by Area of Expansion
• Table 16.75 Most Active Players: Distribution by Number of Expansions
• Table 16.76 Recent Expansions: Distribution by Location of Facility (Continent-wise)
• Table 16.77 Recent Expansions: Distribution by Location of Facility (Country-wise)
• Table 16.78 Recent Expansions: Distribution by Type of Expansion and Location of Facility
• Table 16.79 Global Demand for Cell Therapy Consumables for Planar Process, till 2035 (Million Liters)
• Table 16.80 Global Demand for Cell Therapy Consumables for Suspension Process, till 2035 (Million Liters)
• Table 16.81 Global Demand for Cell Therapy Consumables for Planar Process, till 2035: Distribution by Scale of Operation (Million Liters)
• Table 16.82 Global Demand for Cell Therapy Consumables for Suspension Process, till 2035: Distribution by Scale of Operation (Million Liters)
• Table 16.83 Global Demand for Cell Therapy Consumables: Distribution by Geography, Current Year and 2035
• Table 16.84 Global Demand for Cell Therapy Consumables for Planar Process, till 2035: Distribution by Geography (Million Liters)
• Table 16.85 Global Demand for Cell Therapy Consumables for Suspension Process, till 2035: Distribution by Geography (Million Liters)
• Table 16.86 Global Cell Therapy Consumables Market, till 2035 (USD Million)
• Table 16.87 Cell Therapy Consumables Market: Distribution by Type of Product, Current Year and 2035
• Table 16.88 Cell Therapy Consumables Market for Extracellular Matrices, till 2035 (USD Million)
• Table 16.89 Cell Therapy Consumables Market for Kits, till 2035 (USD Million)
• Table 16.90 Cell Therapy Consumables Market for Media, till 2035 (USD Million)
• Table 16.91 Cell Therapy Consumables Market for Reagents, till 2035 (USD Million)
• Table 16.92 Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2023, 2028 and 2035
• Table 16.93 Cell Therapy Consumables Market for Dendritic Cell Therapies, till 2035 (USD Million)
• Table 16.94 Cell Therapy Consumables Market for NK Cell Therapies, till 2035 (USD Million)
• Table 16.95 Cell Therapy Consumables Market for Stem Cell Therapies, till 2035 (USD Million)
• Table 16.96 Cell Therapy Consumables Market for T-Cell Therapies, till 2035 (USD Million)
• Table 16.97 Cell Therapy Consumables Market: Distribution by Scale of Operation, Current Year and 2035
• Table 16.98 Cell Therapy Consumables Market for Clinical Operations, till 2035 (USD Million)
• Table 16.99 Cell Therapy Consumables Market for Commercial Operations, till 2035 (USD Million)
• Table 16.100 Cell Therapy Consumables Market: Distribution by Type of End-User, Current Year and 2035
• Table 16.101 Cell Therapy Consumables Market for Industry Players, till 2035 (USD Million)
• Table 16.102 Cell Therapy Consumables Market for Non-Industry Players, till 2035 (USD Million)
• Table 16.103 Cell Therapy Consumables Market: Distribution by Geography, Current Year and 2035
• Table 16.104 Cell Therapy Consumables Market in North America, till 2035 (USD Million)
• Table 16.105 Cell Therapy Consumables Market in the US, till 2035 (USD Million)
• Table 16.106 Cell Therapy Consumables Market in Canada, till 2035 (USD Million)
• Table 16.107 Cell Therapy Consumables Market in Rest of North America, till 2035 (USD Million)
• Table 16.108 Cell Therapy Consumables Market in Europe, till 2035 (USD Million)
• Table 16.109 Cell Therapy Consumables Market in Spain, till 2035 (USD Million)
• Table 16.110 Cell Therapy Consumables Market in France, till 2035 (USD Million)
• Table 16.111 Cell Therapy Consumables Market in Germany, till 2035 (USD Million)
• Table 16.112 Cell Therapy Consumables Market in the UK, till 2035 (USD Million)
• Table 16.113 Cell Therapy Consumables Market in Italy, till 2035 (USD Million)
• Table 16.114 Cell Therapy Consumables Market in Netherlands, till 2035 (USD Million)
• Table 16.115 Cell Therapy Consumables Market in Rest of Europe, till 2035 (USD Million)
• Table 16.116 Cell Therapy Consumables Market in Asia-Pacific, till 2035 (USD Million)
• Table 16.117 Cell Therapy Consumables Market in China, till 2035 (USD Million)
• Table 16.118 Cell Therapy Consumables Market in Japan, till 2035 (USD Million)
• Table 16.119 Cell Therapy Consumables Market in Rest of Asia-Pacific, till 2035 (USD Million)
• Table 16.120 Cell Therapy Consumables Market in Middle East and North Africa, till 2035 (USD Million)
• Table 16.121 Cell Therapy Consumables Market in Latin America, till 2035 (USD Million)